Literature DB >> 23461525

Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies.

Yu Song1, Hongwei Nie, Yong Xu, Ling Zhang, Yan Wu.   

Abstract

Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, which were thought to have a positive impact on dementia. We carried out the present meta-analysis to investigate whether statins might be associated with a reduction on risk of dementia. We carried out a meta-analysis of prospective cohort studies to examine the risk of dementia associated with statins. Ovid-Medline database, PubMed database, Springer Link database and Google Scholar in English search were carried out for relevant studies. Selected studies had to describe an original study defined by strict screening and diagnostic criteria. We included eight prospective cohort studies that reported relative risks with 95% confidence intervals for the association of statins and dementia risk. A random effects model was used to calculate the summary risk estimates. The studies eligible for analysis involved 2851 cases and 57020 participants. The summary relative risk of dementia for the use of statins was 0.62 (95% confidence interval 0.43-0.81), with evidence of heterogeneity (P = 0.001, I(2) = 70.8%). Findings of the present meta-analysis show that statin use was associated with a reduced risk of dementia.
© 2013 Japan Geriatrics Society.

Entities:  

Keywords:  cohort studies; dementia; intervention; meta-analysis; statins

Mesh:

Substances:

Year:  2013        PMID: 23461525     DOI: 10.1111/ggi.12044

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN: 1447-0594            Impact factor:   2.730


  21 in total

Review 1.  Impact on cognitive function-are all statins the same?

Authors:  Nishant P Shah; Kristopher J Swiger; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 2.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

Review 3.  Strategies for dementia prevention: latest evidence and implications.

Authors:  Gopalkumar Rakesh; Steven T Szabo; George S Alexopoulos; Anthony S Zannas
Journal:  Ther Adv Chronic Dis       Date:  2017-06-27       Impact factor: 5.091

Review 4.  Cholesterol, statins, and dementia: what the cardiologist should know.

Authors:  Brett L Wanamaker; Kristopher J Swiger; Roger S Blumenthal; Seth S Martin
Journal:  Clin Cardiol       Date:  2015-04-13       Impact factor: 2.882

5.  PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.

Authors:  Kristopher J Swiger; Seth S Martin
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

6.  Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Authors:  Robert P Giugliano; Francois Mach; Kenton Zavitz; Christopher Kurtz; Jingjing Schneider; Huei Wang; Anthony Keech; Terje R Pedersen; Marc S Sabatine; Peter S Sever; Narimon Honarpour; Scott M Wasserman; Brian R Ott
Journal:  Clin Cardiol       Date:  2017-02-16       Impact factor: 2.882

7.  Bridging the Translation Gap: From Dementia Risk Assessment to Advice on Risk Reduction.

Authors:  Kaarin J Anstey; Ranmalee Eramudugolla; Diane E Hosking; Nicola T Lautenschlager; Roger A Dixon
Journal:  J Prev Alzheimers Dis       Date:  2015

Review 8.  Molecular targets of statins and their potential side effects: Not all the glitter is gold.

Authors:  Kush K Patel; Viren S Sehgal; Khosrow Kashfi
Journal:  Eur J Pharmacol       Date:  2022-03-20       Impact factor: 4.432

Review 9.  Statins for the prevention of dementia.

Authors:  Bernadette McGuinness; David Craig; Roger Bullock; Peter Passmore
Journal:  Cochrane Database Syst Rev       Date:  2016-01-04

10.  Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research.

Authors:  Colm Cunningham; Edel Hennessy
Journal:  Alzheimers Res Ther       Date:  2015-03-24       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.